Osimertinib versus osimertinib plus chemotherapy for non–small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial
Kentaro Tanaka(Institute for the Future), Isamu Okamoto(Kyushu University Hospital), Kosuke Hamai(Hiroshima Prefectural Hospital), Kunihiko Kobayashi(Saitama International Medical Center), Satoshi Oizumi(Hokkaido University), Yukari Tsubata(Shimane University), Takahiro Uchida(Tokyo Women's Medical University), Hajime Asahina(Hokkaido University), Yoshihiro Miyata(Hiroshima University), Shunichi Sugawara(Sendai Kousei Hospital), Taishi Harada(Fukuyama City Hospital), Junji Kishimoto(Kyushu University Hospital), Kana Watanabe(Miyagi Prefectural Hospital Organization), Kenji Sugio(University of Occupational and Environmental Health Japan)
Cited by 50
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
|Science Translational Medicine|2011|670